We find that in SCD whole blood samples not treated with crizanlizumab, at early timepoints CD45+ WBCs primarily occlude ends of channels, but this effect is reversed when SCD blood is treated with crizanlizumab (Fig. 6i, Supplementary Fig. 12). The gene discussed is PTPRC; the disease is Schnyder corneal dystrophy.